Abstract
Interest in Central Nervous System (CNS) inflammation has rapidly grown over the past decade driven by the increasing evidence indicating that chronic inflammation and neuroinflammation in the brain may play an important role in the progressive neuronal cell death in many chronic CNS diseases, such as Alzheimer and Parkinson’s diseases, traumatic brain injury, spinal cord injury (SCI), as well as pathologies associated with CNS infections. In peripheral tissues, generally inflammation has a protective role limiting the survival and proliferation of invading pathogens, promoting tissue repair and recovery. This innate response normally resolves over a few weeks, accompanyied by tissue repair aided by macrophages recruited to the site. However, when the inflammatory response does not undergo resolution, it might turn into chronic inflammation. Any chronic inflammatory process can damage healthy tissue and the brain may be particularly vulnerable, since destroyed neurons can not be replaced. Recently, several reports have suggested that phosphodiesterases (PDEs) are new targets for central nervous system (CNS) diseases. All the PDEs are expressed in the CNS, making this gene family a particularly attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders. Significantly, all neurons express multiple PDEs, which differ in cyclic nucleotide specificity, affinity, regulatory control and subcellular compartmentalization. Therefore, PDEs inhibition represents a mechanism through which it could be possible to precisely modulate neuronal activity. In this article, we review the current state of art of PDEs in the CNS diseases associated with neuroinflammation.
Keywords: Alzheimer’s disease, chronic Inflammation, neuroinflammation, Parkinson’s disease, PDE inhibitors, spinal cord injury.
Current Medicinal Chemistry
Title:Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases
Volume: 21 Issue: 24
Author(s): Irene Paterniti, Emanuela Esposito and Salvatore Cuzzocrea
Affiliation:
Keywords: Alzheimer’s disease, chronic Inflammation, neuroinflammation, Parkinson’s disease, PDE inhibitors, spinal cord injury.
Abstract: Interest in Central Nervous System (CNS) inflammation has rapidly grown over the past decade driven by the increasing evidence indicating that chronic inflammation and neuroinflammation in the brain may play an important role in the progressive neuronal cell death in many chronic CNS diseases, such as Alzheimer and Parkinson’s diseases, traumatic brain injury, spinal cord injury (SCI), as well as pathologies associated with CNS infections. In peripheral tissues, generally inflammation has a protective role limiting the survival and proliferation of invading pathogens, promoting tissue repair and recovery. This innate response normally resolves over a few weeks, accompanyied by tissue repair aided by macrophages recruited to the site. However, when the inflammatory response does not undergo resolution, it might turn into chronic inflammation. Any chronic inflammatory process can damage healthy tissue and the brain may be particularly vulnerable, since destroyed neurons can not be replaced. Recently, several reports have suggested that phosphodiesterases (PDEs) are new targets for central nervous system (CNS) diseases. All the PDEs are expressed in the CNS, making this gene family a particularly attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders. Significantly, all neurons express multiple PDEs, which differ in cyclic nucleotide specificity, affinity, regulatory control and subcellular compartmentalization. Therefore, PDEs inhibition represents a mechanism through which it could be possible to precisely modulate neuronal activity. In this article, we review the current state of art of PDEs in the CNS diseases associated with neuroinflammation.
Export Options
About this article
Cite this article as:
Paterniti Irene, Esposito Emanuela and Cuzzocrea Salvatore, Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases, Current Medicinal Chemistry 2014; 21 (24) . https://dx.doi.org/10.2174/0929867321666140217102428
DOI https://dx.doi.org/10.2174/0929867321666140217102428 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pro-Drugs for Indirect Cannabinoids as Therapeutic Agents
Current Drug Delivery Stem Cells and Nanoparticles in Therapy
Nanoscience & Nanotechnology-Asia Immunomodulatory Properties of Farnesoids: The New Steroids?
Current Medicinal Chemistry Targeting the Prokineticin System to Control Chronic Pain and Inflammation
Current Medicinal Chemistry Metabotropic GABAB Receptors New Challenges in Drug Design
Current Medicinal Chemistry - Central Nervous System Agents Fe-S Proteins Acting as Redox Switch: New Key Actors of Cellular Adaptive Responses
Current Chemical Biology Innovative Concepts of Cell Therapy: Pluripotent and Multipotent Stem Cells and New Bio-Material Solution in Research and Clinical Application
Recent Patents on Regenerative Medicine Evaluation of Pregabalin Therapy in Peripheral Neuropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) p38 MAPK: A Potential Target of Chronic Pain
Current Medicinal Chemistry Neuropeptides as Possible Targets in Sleep Disorders: Special Emphasis on Hypocretin-Deficient Narcolepsy
CNS & Neurological Disorders - Drug Targets Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews Chemotherapy-Induced Peripheral Neuropathic Pain and Rodent Models
CNS & Neurological Disorders - Drug Targets Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Current Neuropharmacology The Metabotropic Glutamate Receptor System: G-Protein Mediated Pathways that Modulate Neuronal and Vascular Cellular Injury
Current Medicinal Chemistry - Central Nervous System Agents Tonic and Rhythmic Spinal Activity Underlying Locomotion
Current Pharmaceutical Design Mesenchymal Stem Cells in Veterinary Regenerative Therapy: Basic Physiology and Clinical Applications
Current Stem Cell Research & Therapy Disrupted Functional Connectivity Related to Differential Degeneration of the Cingulum Bundle in Mild Cognitive Impairment Patients
Current Alzheimer Research Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients
Current Vascular Pharmacology